Coya Therapeutics (COYA) Operating Expenses (2022 - 2026)
Coya Therapeutics (COYA) posted Operating Expenses of $7.9 million for Q1 2026, down 21.01% sequentially from $10.0 million in Q4 2025, and down 0.55% YoY from $7.9 million in Q1 2025.
Coya Therapeutics (COYA) Operating Expenses (2022 - 2026) Analysis & Trends
Coya Therapeutics has reported Operating Expenses for 5 years, with the latest figure at $7.9 million in Q1 2026.
- Quarterly Operating Expenses fell 0.55% year-over-year to $7.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.5 million (up 31.69% YoY) and the FY2025 annual result came in at $30.5 million, up 46.61% from the prior year.
- Operating Expenses slipped to $7.9 million in Q1 2026 per COYA's latest filing, from $10.0 million in the prior quarter.
- Over five years, Operating Expenses peaked at $10.0 million in Q4 2025 and troughed at $1.7 million in Q1 2022.
- A 5-year average of $4.9 million and a median of $4.2 million in 2023 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2023 and 2025: Operating Expenses slipped 5.57% in 2023, then jumped 144.74% in 2025.
- Over 5 years, Operating Expenses stood at $2.0 million in 2022, then soared by 108.98% to $4.2 million in 2023, then declined by 2.5% to $4.1 million in 2024, then surged by 144.74% to $10.0 million in 2025, then retreated by 21.01% to $7.9 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $7.9 million, $10.0 million, and $6.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Coya Therapeutics | 113.30 Mn | 70.10 Mn | - | 7.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.29 Mn |
| Mar 31, 2026 | 7.89 Mn |
| Dec 31, 2025 | 9.99 Mn |
| Sep 30, 2025 | 6.00 Mn |
| Jun 30, 2025 | 6.58 Mn |
| Mar 31, 2025 | 7.93 Mn |
| Dec 31, 2024 | 4.08 Mn |
| Sep 30, 2024 | 4.45 Mn |
| Jun 30, 2024 | 6.66 Mn |
| Mar 31, 2024 | 5.61 Mn |
| Dec 31, 2023 | 4.19 Mn |
| Sep 30, 2023 | 3.56 Mn |
| Jun 30, 2023 | 3.25 Mn |
| Mar 31, 2023 | 2.90 Mn |
| Dec 31, 2022 | 2.00 Mn |
| Sep 30, 2022 | 2.66 Mn |
| Jun 30, 2022 | 3.45 Mn |
| Mar 31, 2022 | 1.70 Mn |